Preclinical Antimalarial Combination Study of M5717, a Plasmodium falciparum Elongation Factor 2 Inhibitor, and Pyronaridine, a Hemozoin Formation Inhibitor

Antimalarial drug resistance in the Plasmodium falciparum parasite poses a constant challenge for drug development. To mitigate this risk, new antimalarial medicines should be developed as fixed-dose combinations. Assessing the pharmacodynamic interactions of potential antimalarial drug combination...

Descripción completa

Detalles Bibliográficos
Autores principales: Rottmann, Matthias, Jonat, Brian, Gumpp, Christin, Dhingra, Satish K., Giddins, Marla J., Yin, Xiaoyan, Badolo, Lassina, Greco, Beatrice, Fidock, David A., Oeuvray, Claude, Spangenberg, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2020
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7179297/
https://www.ncbi.nlm.nih.gov/pubmed/32041711
http://dx.doi.org/10.1128/AAC.02181-19

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7179297/
https://www.ncbi.nlm.nih.gov/pubmed/32041711
http://dx.doi.org/10.1128/AAC.02181-19

Ejemplares similares